Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures.~The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria.~The following is the general sequence of events during the 28-day evaluation period:~Completion of baseline procedures Participants were assessed for 28 days and completed all safety monitoring.
The purpose of this study was to observe real-world disease progression in mild-moderate COVID-19 patients with at least one risk factor for serve COVID-19 illness or death.